Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BB102 in advanced or unresectable FGF19-overexpressing hepatocellular carcinoma
CTR20254460Phase 2Active
- Sponsor
- Bohui Biotech
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BB102 in hepatocellular carcinoma (HCC), sponsored by Bohui Biotech. Started Dec 2025; status: active.
02
Drugs
BB102
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20254460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254460.